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Decrease of Skin Infiltrating and Circulating CCR10þ
T Cells Coincides with Clinical Improvement after
Topical Tacrolimus in Omenn Syndrome
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TO THE EDITOR
Omenn syndrome (OS) is a rare form of
severe combined immunodeficiency
characterized by an early onset of
generalized erythrodermia caused by a
massive auto-reactive T-cell infiltrate of
the skin. Activated T cells infiltrate the
skin, gut, liver, and spleen, resembling
graft-versus-host disease (Rieux-Laucat
et al., 1998).
Lymphocyte expression of surface
adhesion molecules and chemokineAbbreviation: OS, Omenn syndrome
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receptors is required for appropriate
tissue and microenvironmental locali-
zation, such as homing to the skin
(Hwang, 2001). T cells with skin trop-
ism are identified by cutaneous lym-
phocyte antigen expression and by the
expression of two chemokine receptors,
CCR4 and CCR10, the ligands of
which, CCL17 and CCL27, are pro-
duced in the skin. Skin-homing T cells
have been shown to have an important
function in many inflammatory skin
diseases (Santamaria Babi et al.,
1995).
One way to modulate T-cell activity
is by the use of immunosuppressive
drugs belonging to the group of calci-
neurin inhibitors such as tacrolimus
(Ho et al., 1996). It is effective in the
treatment of various skin diseases such
as psoriasis and atopic dermatitis
(Carroll and Fleischer, 2004). We
describe a unique skin-homing profile
on circulating CD4þ and CD8þ
T cells of an OS patient and the effect
of topical tacrolimus treatment on these
T-cell populations.
The patient (OS1) was born at term
from consanguineous parents after an
uncomplicated pregnancy. His older
sister is healthy and family history is
negative for immunodeficiencies, but
positive for atopy. Within the first 2.5
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Figure 1. Decrease of circulating CCR10þ T cells and normalization of skin histology during tacrolimus treatment of a patient with Omenn syndrome (OS1).
(a) Flow cytometry shows an increased percentage of circulating CD4þCCR10þ and CD8þCCR10þ T cells. Tacrolimus treatment resulted in a substantial
decrease in the number of these T cells. Numbers in the plots represent the percentage of CCR10þ cells within CD4þ or CD8þ T cells. This decrease is
also true for the absolute numbers as depicted in (b). The significant cutaneous improvement on topical tacrolimus treatment is depicted in (c). (d) Before
treatment, an active lesion with prominent epidermal hyperplasia (H&E stain; scale bar¼10 mm), a large T-cell infiltrate of both CD4þ (green) and CD8þ
T cells (yellow; scale bar¼ 50mm), a reduced epidermal expression of CD1aþ Langerhans cells (red; scale bar¼50 mm), and a strong expression of CCL27
(single enzymatic staining; scale bar¼5 mm) are observed. During treatment, normal skin histology was restored with a limited T-cell infiltrate, an increased
number of epidermal CD1aþ cells and a basal expression of CCL27 (comparable with healthy control skin, data not shown). Immunohistochemical analysis
was performed as described previously (Faaij et al., 2006). The dotted white line represents the epidermal–dermal border.
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months of his life, he presented with
erythematous skin lesions, food intoler-
ance, enteritis, rhinitis, fever (38–391C),
dyspnea, generalized lymphadenopa-
thy, conjunctivitis, and otitis externa.
Blood examination showed leukocyto-
sis (27 109 l1) with a marked eosino-
philia of 20–30%.
Lymphocyte subset analysis showed
that virtually all CD3þ cells were T-cell
receptor a/b and CD45RO positive and
that circulating B cells were lacking.
Chimerism analysis excluded transfer-
red maternal T lymphocytes. Therefore,
the patient was diagnosed as having
severe combined immunodeficiency
with an OS presentation. Genetic analy-
sis revealed a homozygous deletion
(c.591delT) in the RAG1 gene, resulting
in a frame shift and a premature termina-
tion at amino-acid position 200.
The skin-homing capacity of circulat-
ing T cells was investigated. Flow
cytometry revealed high percentages of
CCR10 on CD4þ (57.7%) and CD8þ
(66.6%) T cells (Figure 1a). These T cells
co-expressed the activation marker HLA-
DR (51.5% of CD4þCCR10þ and
61.1% of CD8þCCR10þ ) and cuta-
neous lymphocyte antigen (88.4% of
CD4þCCR10þ and 93.2% of CD8þ
CCR10þ ; data not shown). High per-
centages of circulating CD4þCCR10þ
and CD8þCCR10þ T cells were also
observed in another unrelated OS patient
(OS2) with similar cutaneous manifesta-
tions (data not shown). Although CCR10
has been clearly associated with the
homing of CD4þ T cells to the skin
(Homey et al., 2002; Faaij et al., 2006),
few reports indicate an involvement of
CD8þ T cells (Hudak et al., 2002). The
observation of such a large percentage of
CD8þCCR10þ T cells in an inflam-
matory disorder is, to our knowledge,
previously unreported.
Topical tacrolimus (Astellas Pharma
Europe Ltd, Leiderdrop, Netherlands)
was applied to bridge the time to
hematopoietic stem cell transplanta-
tion, the only curative procedure for
this disease (Antoine et al., 2003;
Mazzolari et al., 2005). Topical treat-
ment resulted in significant cutaneous
improvement within 48 hours. During
7 weeks of treatment (until the start of
myeloablative conditioning), tacroli-
mus blood levels varied between 1.9
and 12.8 ng ml1, which was accom-
panied by a further reduction in ery-
throdermia even in nontreated skin
areas (Figure 1c). Other systemic man-
ifestations were not significantly im-
proved. This seems in contrast with a
previous report in which oral tacroli-
mus failed to control erythrodermia in a
child with OS (Rego et al., 2006).
Although achieving similar blood levels
(between 1.8 and 4.4 ng ml1), the
main difference seems to be the route
of administration.
We investigated whether this treat-
ment had an effect on circulating skin-
homing T cells. Figure 1a depicts a
substantial decrease in the percentage
of both CD4þCCR10þ and CD8þ
CCR10þ T cells 7 weeks after the start
of treatment. A considerable reduction
is also observed in the absolute num-
bers of CD4þCCR10þ (17.4 times
lower) and CD8þCCR10þ (224.5
times lower) T cells. This decrease is
much higher than that of the total
CD4þ (5.1 times lower) and CD8þ
(7.7 times lower) populations, indi-
cating the specificity of the decline
(Figure 1b).
Similarly, the preexisting dense skin
infiltrate of both CD4þ and CD8þ
T cells was significantly reduced, whereas
the number of CD1aþ Langerhans cells
increased in the epidermis during treat-
ment. Immunohistochemical analysis
showed a complete reversion of the
abundant expression of the CCR10 ligand,
CCL27, in the epidermis of the affected
skin after tacrolimus treatment (Figure 1d).
Previous reports on the Th1/Th2
profile of T cells from OS patients have
given conflicting results (Harville et al.,
1997; Villa et al., 1999). Here, the
CCR10þ T cells from OS1 before
treatment clearly produced pro-inflam-
matory cytokines TNF-a (CD4þ : 63.5%
and CD8þ : 70.4%) and IL-2 (CD4þ :
54.4% and CD8þ : 92.2%), but only
marginally produced anti-inflammatory
cytokines (IL-4 and IL-5) on in vitro
stimulation with PMA/ionomycin. How-
ever, during treatment, TNF-a and IL-2
production by the CCR10þ T cells was
significantly diminished (Figure 2). Simi-
lar effects on cytokine production were
observed in cultures of PBMC exposed to
tacrolimus (data not shown).
The reduction of dermal T-cell num-
bers could be explained by the fact that
TNF-a is known to stimulate CCL27
production by keratinocytes (Vester-
gaard et al., 2004, 2005). Reduction of
TNF-a may have caused the decline of
CCL27 expression in the skin, leading
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Figure 2. Intracellular cytokine staining reveals a pro-inflammatory profile of the circulating CCR10þ
T cells from OS1, which is reduced upon topical tacrolimus treatment. Intracellular staining of
cytokines (IFN-g, TNF-a, IL-2, IL-4, and IL-5) produced by circulating CD4þCCR10þ and CD8þCCR10þ
T cells on PMA/ionomycin stimulation in vitro before and during topical tacrolimus treatment.
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to a subsequently diminished recruit-
ment of T cells. Tacrolimus could also
have a direct effect on CCR10 expres-
sion by T cells, as has been shown for
other immunosuppressive drugs (Moed
et al., 2004; Park et al., 2005; Caproni
et al., 2007). However, we were unable
to carry out these experiments.
In summary, our findings illustrate
that topical tacrolimus treatment has the
potential to reduce a CD4/CD8 T-cell-
mediated skin inflammatory process by
the downregulation of skin-specific
chemokines and chemokine receptors.
Informed consent was obtained from
parents regarding the use of photographs.
Institutional approval is provided to use
leftover biological material obtained for
diagnostic purposes for related research in
line with the Helsinki guidelines.
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Pemphigus Vulgaris in White Europeans Is Linked with
HLA Class II Allele HLA DRB1*1454 but Not DRB1*1401
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TO THE EDITOR
Population studies have consistently
shown a link between certain class II
HLA alleles and ethnic groups in patients
with pemphigus vulgaris (PV). In parti-
cular, HLA DRB1*04 and *14 and
DQB1*0503 and *0302 alleles (Tron
et al., 2005) have been shown to be
strongly associated with PV. Although
previous studies have suggested that PV
is associated with DRB1*1401 in a
number of populations from Europe andAbbreviation: PV, pemphigus vulgaris
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